Clinical Trial Update: One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity [Phase 3]

View source ↗

Summary

Phase 3 open-label dose-escalation long-term safety study in multiple sclerosis patients with spasticity completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spasticity

Snippet

Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Multiple Sclerosis, Spasticity | Phase 3 | Status: COMPLETED